Sandbox g55: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
Line 1: Line 1:


{{PBI|Enterobacter}}
{{PBI|Enterobacter}}
:* '''Enterobacter species including E. aerogenes and E. cloacae'''
:* '''Enterobacter species including <i>E. aerogenes</i> and <i>E. cloacae</i>'''
::* 1. '''Non–life-threatening infections or MDR-GNB prevalence &lt; 20%'''
::* 1. '''Non–life-threatening infections or MDR-GNB prevalence &lt; 20%'''
:::* 1.1 '''Empiric antimicrobial therapy'''
:::* 1.1 '''Empiric antimicrobial therapy pending <i>in vitro</i> susceptibility'''
::::* Preferred regimen: [[Piperacillin-Tazobactam]] 3.375 mg IV q6h
::::* Preferred regimen: [[Piperacillin-Tazobactam]] 3.375 mg IV q6h
::::* Alternative regimen: [[Ciprofloxacin]] 400 mg IV q12h
::::* Alternative regimen: [[Ciprofloxacin]] 400 mg IV q12h
:::* 1.2 '''<i>In vitro</i> susceptibility available'''
::::* 1.2.1 '''Susceptible to all tested drugs'''
:::::* Preferred regimen: [[Piperacillin-Tazobactam]] 3.375 mg IV q6h
:::::* Alternative regimen (1): [[Ciprofloxacin]] 400 mg IV q12h or Cefepime 2 gm IV q8h
:::::* Alternative regimen (2): [[Cefepime]] 2 gm IV q8h





Revision as of 03:27, 22 July 2015

  • Enterobacter species including E. aerogenes and E. cloacae
  • 1. Non–life-threatening infections or MDR-GNB prevalence < 20%
  • 1.1 Empiric antimicrobial therapy pending in vitro susceptibility
  • 1.2 In vitro susceptibility available
  • 1.2.1 Susceptible to all tested drugs





  • Acanthamoeba species



  • Balamuthia mandrillaris



References